The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeris Biopharma Regulatory News (0A8E)

Share Price Information for Xeris Biopharma (0A8E)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.861111
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.861111
0A8E Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Xeris Pharmaceuticals, Inc 8.3 Amend

11 Aug 2021 16:35

RNS Number : 3542I
J.P. Morgan Securities LLC
11 August 2021
 

Ap19

 

 

 

AMENDMENT

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC

Company dealt in

Xeris Pharmaceuticals, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

$0.001 common stock

Date of dealing

09 August 2021

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

3,554,322 5.35

134,114 0.20

(2) Derivatives (other than options)

124,443 0.19

 

(3) Options and agreements to purchase/sell

 

 

Total

3,678,765 5.54

134,114 0.20

       

 

 

 

 

1. DEALINGS (Note 4)

 

(a) Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD)

 

(Note 5)

Purchase(New Borrow)

 

Purchases

 

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

1,100

 

352

 

 1,500

 500

 8,300

 3,950

 13,719

 10,400

 53,564

 11,100

 657

 700

 15,769

 35,730

 9,527

 3,611

 10,065

 10,900

 13,200

 4,500

 23,112

 2,000

 1,095

 6,990

 30,725

 16,911

 9,918

 8,482

 5,443

 17,803

 2,100

 10,296

 2,933

 600

 12,582

 4,000

 4,279

 8,642

 2,403

 24,818

 2,500

 9,281

 1,700

 1,235

 4,102

 4,781

 10,510

 7,607

 19,378

 2,854

 13,600

N/A

 

2.4100 USD

2.3250 USD

2.3350 USD

2.3550 USD

2.3557 USD

2.3650 USD

2.4000 USD

2.4023 USD

2.4050 USD

2.4054 USD

2.4057 USD

2.4069 USD

2.4079 USD

2.4090 USD

2.4092 USD

2.4100 USD

2.4113 USD

2.4129 USD

2.4149 USD

2.4150 USD

2.4190 USD

2.4200 USD

2.4220 USD

2.4242 USD

2.4250 USD

2.4263 USD

2.4285 USD

2.4300 USD

2.4308 USD

2.4321 USD

2.4327 USD

2.4332 USD

2.4333 USD

2.4350 USD

2.4353 USD

2.4370 USD

2.4375 USD

2.4400 USD

2.4450 USD

2.4452 USD

2.4455 USD

2.4468 USD

2.4500 USD

2.4545 USD

2.4547 USD

2.4550 USD

2.4553 USD

2.4567 USD

2.4600 USD

2.4650 USD

 

 

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(USD) (Note 5)

 

 

 

 

 

 

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

 

Ap21

 

2. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

None

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)  NO

 

Date of disclosure

 11 August 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISESFDFIFEFSEDA
Date   Source Headline
7th Oct 20213:09 pmRNSXeris Pharmaceuticals, Inc 8.3
6th Oct 20212:43 pmRNSXeris Pharmaceuticals, Inc 8.3
6th Oct 20212:42 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
5th Oct 20215:06 pmRNSXeris Pharmaceuticals, Inc 8.3 Amend
5th Oct 20213:15 pmRNSXeris Pharmaceuticals, Inc 8.3
4th Oct 20211:04 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Oct 20213:05 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Oct 202110:14 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
30th Sep 20215:07 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Sep 20212:58 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Sep 202110:22 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
29th Sep 20212:36 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Sep 20212:22 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Sep 20212:21 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
28th Sep 20212:19 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
27th Sep 202112:27 pmRNSXeris Pharmaceuticals, Inc 8.3
24th Sep 20214:35 pmRNSXeris Pharmaceuticals, Inc 8.3
24th Sep 20211:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
23rd Sep 20212:35 pmRNSXeris Pharmaceuticals, Inc 8.3
23rd Sep 20212:18 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
22nd Sep 20213:00 pmRNSXeris Pharmaceuticals, Inc 8.3
22nd Sep 20212:12 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
22nd Sep 202112:18 pmRNSForm 8.3 - XERIS PHARMACEUTICALS INC
21st Sep 20213:03 pmRNSXeris Pharmaceuticals, Inc 8.3
21st Sep 20212:17 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
21st Sep 20211:40 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
20th Sep 20211:53 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
20th Sep 202112:29 pmRNSXeris Pharmaceuticals, Inc 8.3
20th Sep 202112:14 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceutical Inc.
17th Sep 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
17th Sep 20212:51 pmRNSXeris Pharmaceuticals, Inc 8.3
17th Sep 20212:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
17th Sep 20211:13 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
16th Sep 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
16th Sep 20212:46 pmRNSXeris Pharmaceuticals, Inc 8.3
16th Sep 20211:58 pmGNWInvesco Ltd: Form 8.3 - Xeris Pharmaceutical Inc
16th Sep 202110:52 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
15th Sep 20211:58 pmRNSXeris Pharmaceuticals, Inc 8.3
15th Sep 202111:15 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
15th Sep 202111:14 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
14th Sep 20212:24 pmRNSXeris Pharmaceuticals, Inc 8.3
14th Sep 20211:56 pmRNSMan Group PLC : Form 8.3 - Strongbridge biopharma plc
14th Sep 20211:03 pmRNSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
13th Sep 202112:22 pmRNSXeris Pharmaceuticals, Inc 8.3
13th Sep 202112:15 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
10th Sep 20212:42 pmRNSXeris Pharmaceuticals, Inc 8.3
10th Sep 20217:21 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
9th Sep 20211:49 pmRNSXeris Pharmaceuticals, Inc 8.3
9th Sep 202111:15 amRNSForm 8.3 - Xeris Pharmaceuticals, Inc
9th Sep 202111:13 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.